Mahesh Patel V
Known title: CEO and PresidentCIK: 0001579872
Mahesh Patel V's purchase track record
How the stock did after each of Mahesh Patel V's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
7
of 7 since November 18, 2021
Stock higher 6 months later
14%
3 months: 57%
Median 6-month return
-33.6%
3 months: +2.0%
Beat the S&P 500
0%
median -38.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/2/2026 | LPCN | $101K | +16.6% | +1.0% | +16.5% |
| 5/25/2023 | LPCN | $44K | -20.9% | -52.0% | +9.8% |
| 3/17/2023 | LPCN | $65K | -18.0% | -38.5% | +13.6% |
| 11/14/2022 | LPCN | $29K | +42.1% | -33.6% | +4.5% |
| 9/27/2022 | LPCN | $41K | +2.0% | -16.3% | +8.9% |
| 5/16/2022 | LPCN | $38K | -10.9% | -51.9% | -1.3% |
| 11/18/2021 | LPCN | $27K | +11.9% | -18.3% | -17.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LPCN | ▲ Buy | Open Market | 25,000 | $51K | 4/6/2026 | View on chart |
| LPCN | ▲ Buy | Open Market | 25,000 | $51K | 4/2/2026 | View on chart |
| LPCN | ▲ Buy | Grant | 4,893 | $0 | 3/8/2024 | View on chart |
| LPCN | ▲ Buy | Open Market | 8,706 | $44K | 5/25/2023 | View on chart |
| LPCN | ▲ Buy | Open Market | 150,000 | $48K | 3/24/2023 | View on chart |
| LPCN | ▲ Buy | Open Market | 50,000 | $17K | 3/17/2023 | View on chart |
| LPCN | ▲ Buy | Open Market | 75,000 | $29K | 11/14/2022 | View on chart |
| LPCN | ▲ Buy | Open Market | 100,000 | $41K | 9/27/2022 | View on chart |
| LPCN | ▲ Buy | Open Market | 50,000 | $38K | 5/16/2022 | View on chart |
| LPCN | ▲ Buy | Open Market | 25,000 | $27K | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Lipocine Partner Verity Gets Health Canada Approval for TLANDO
Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.
Lipocine Partner Verity Gets Health Canada Approval for TLANDO. Lipocine's licensing partner, Verity Pharmaceuticals, received Health Canada approval for TLANDO capsules used in testosterone replacement therapy. This regulatory milestone is relevant to Lipocine as it validates the commercial potential of the licensed product. The stock is currently trading near its 52-week high, reflecting strong recent momentum.